SLC5A2 and diabetes mellitus: Empagliflozin, the SGLT-2 inhibitor—developed to attenuate the glucose reabsorption by the kidneys as a strategy to reduce blood glucose levels in diabetes patients—improves both hyperglycaemia-induced monocyte and endothelial cell dysfunction by glucose transport-independent mechanisms.